Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
Pharmaceutical Technology
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.
pharminent
July 10, 2026 (Last updated: July 10, 2026)
Pharmaceutical Technology
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.